Heimfeld S S - OmicsDI

Previous page
1 / 3
You're on page 1
page 2
page 3
Next page

Sort by:

Relevance

Page size

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Not available

S-EPMC5590803 | biostudies-literature

Transcription profiling of human CD34+ cells from bone marrow and G-CSF-mobilized peripheral blood to investigate why the latter are optimal for allogeneic transplant recipients

Comparison of gene expression in CD34+ cells from bone marrow and G-CSF-mobilized peripheral blood to investigate why the latter are optimal for allogeneic transplant recipients.

ORGANISM(S): Homo sapiens

2008-06-13 | E-GEOD-500 | biostudies-arrayexpress

Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

Not available

S-EPMC4489995 | biostudies-literature

MIR144 and MIR451 regulate human erythropoiesis via RAB14.

Not available

S-EPMC4314389 | biostudies-literature

Genome-wide characterization of MED12 occupancy in human CD34+ cells

We report ChIP-Seq data for MED12 in human CD34+ cells. Med12 occupies promoter distal regions that regulate specific transcriptional programs required for the homeostasis of the hematopoietic system. 50 milion cells were used to perform ChIP from CD34+ cells with 10 ug of antibody

ORGANISM(S): Homo sapiens

2016-08-25 | E-GEOD-75914 | biostudies-arrayexpress

Real Time Immunophenotyping of Leukocyte Subsets Early after Double Cord Blood Transplantation Predicts Graft Function.

Not available

S-EPMC5348257 | biostudies-literature

Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy.

Not available

S-EPMC5080442 | biostudies-literature

Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.

Not available

S-EPMC4563691 | biostudies-literature

Manufacture of Autologous CD34<sup>+</sup> Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.